DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT) announced its participation in the AAAAI 2021 Congress from February 26 to March 1. The company will present findings from a post-hoc analysis of its 12-month Phase 3 PEPITES trial, focusing on the effectiveness of its DBV712 (Viaskin™ Peanut) patch in reducing allergic reactions in children aged 4 to 11. They will also showcase pre-clinical data regarding cashew allergies. Additionally, DBV is sponsoring the FIT Networking Lounge to foster connections among AAAAI fellows.
DBV Technologies has appointed Michele F. Robertson as the new Chief Legal Officer, effective immediately. She brings over 15 years of legal expertise in the biopharma sector, previously serving as General Counsel at Mallinckrodt Pharmaceuticals. Robertson will support DBV's scientific development, regulatory efforts, and corporate governance while facilitating interactions with the FDA. DBV aims to advance its Viaskin™ Peanut product, focusing on meeting the needs of food-allergic patients. The company is positioned for regulatory clarity and strategic growth.
DBV Technologies (Ticker: DBVT) announced CEO Daniel Tassé will participate in a virtual fireside chat at the SVB Leerink Global Partners Healthcare Conference on February 24, 2021, at 8 am ET. The event will be accessible via a live webcast on DBV's website, with a replay available post-event. The company is focused on developing Viaskin™, a proprietary technology for immunotherapy targeting food allergies, including ongoing trials for Viaskin Peanut. DBV Technologies operates globally, with headquarters in Montrouge, France, and offices in the USA.
As of January 31, 2021, the company reported a total of 54,929,187 shares outstanding. This includes 54,883,187 net voting rights, calculated by subtracting shares without voting rights from the total shares. This report adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, detailing its assets as of December 31, 2020. The liquidity account held 112,302 shares and €229,086.53, compared to 24,313 shares and €682,454.94 at contract signing in July 2018. During the second half of 2020, 1,180 purchases and 1,136 sales were executed, totaling 517,291 shares bought for €2,005,858.40 and 458,090 shares sold for €1,841,496.60.
DBV Technologies (Ticker: DBVT) announced on January 14, 2020, that it received feedback from the FDA concerning its Viaskin™ Peanut patch for treating peanut allergies in children aged 4-11. Following a Complete Response Letter, the FDA provided guidance on patch modifications and the need for a new human factors study. DBV aims to start prototype selection in Q1 2021 and plans to submit a safety trial protocol in Q2 2021. The company is optimistic about extending its cash runway to the second half of 2022 due to ongoing restructuring efforts.
DBV Technologies has transitioned to a U.S. domestic issuer, effective January 1, 2021, requiring compliance with SEC regulations. The company will file periodic reports in U.S. dollars and continue with IFRS reporting in Europe. A global restructuring process, approved today, will cut over 200 jobs, leaving a team of 90, expected to enhance operational efficiency for the Viaskin Peanut development. DBV anticipates a 40-50% reduction in monthly cash burn by mid-2021, aiming to extend its cash runway into the second half of 2022.
Monthly Update: As of December 31, 2020, the company reported a total of 54,929,187 shares and 54,929,187 voting rights on the NYSE Euronext Paris. The net voting rights total was 54,816,885, accounting for shares without voting rights.
This disclosure adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency and compliance in reporting shareholding details.
As of November 30, 2020, the company reported a total of 54,929,187 shares outstanding on the NYSE Euronext Paris. The total number of voting rights associated with these shares is 54,929,187, while the net total of voting rights, accounting for shares without voting rights, stands at 54,815,187. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced leadership changes with Dr. Hugh Sampson stepping down as Chief Scientific Officer effective December 1, 2020. He will transition to a role as Scientific Adviser to the CEO, remaining involved with the development of the epicutaneous immunotherapy platform. Dr. Sampson, who has been influential in advancing food allergy treatments, believes this change allows him to refocus on his research at Mount Sinai. DBV’s commitment to the Viaskin technology remains strong as they continue clinical trials aimed at food allergies.